^
    Back
    Association details:
    Biomarker:TMB-L
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:Mekinist (trametinib) (MEK inhibitor) +
    Torin1 (mTOR inhibitor, mTORC2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 1906: Combination MEK and mTORC1/2 inhibition overcomes resistance to single agent therapy in pancreatic cancer

    Published date:
    05/15/2020
    Excerpt:
    In human PDAC xenografts and a syngeneic GEMM, combination treatment of Trametinib and Torin1 dramatically reduced tumor burden and increased survival, without serious toxicity.
    DOI:
    10.1158/1538-7445.AM2020-1906